Multiple patents on original biologics delay when biosimilars get on the market in the US....

“Patent Thickets” on Biologics and What Could Be Done To Chop Them Down to Size – Managed Healthcare Executive

Multiple patents on original biologics delay when biosimilars get on the market in the US. University of Denver Sturm College of Law legal experts argue in a preprint that changes in how the original patents are written could reduce the number of…

 

Read the full article here


-- END RSP MOD -->